hrp0095rfc11.5 | Late Breaking | ESPE2022
Banerjee Indraneel
, D. De Leon Diva
, M. Kendall David
, Birch Sune
, Bøge Eva
, Ivkovic Jelena
, S Thornton Paul
, Nurdan Ciftci
, Huseyin Demirbilek
Background: Congenital hyperinsulinism (CHI) is a chronic and complex rare endocrinopathy with dysregulated insulin secretion causing severe and recurrent hypoglycemia resulting in adverse neurologic and developmental sequelae in children. Current treatment options are limited and often inadequate to treat CHI. Dasiglucagon (DASI), a glucagon analog administered by subcutaneous continuous infusion, has demonstrated reduction in glucose infusion rate (GIR) in P...